Cardio-Cerebro-Vascular Pathophysiology Department, Cardiology Unit, Azienda Sanitaria "Friuli Occidentale", Pordenone, Italy.
Cardio-Cerebro-Vascular Pathophysiology Department, Cardiology Unit, Azienda Sanitaria "Friuli Occidentale", Pordenone, Italy.
Heart Fail Clin. 2021 Apr;17(2):255-262. doi: 10.1016/j.hfc.2021.01.006. Epub 2021 Feb 11.
In recent decades, considerable advances have been made in the treatment of heart failure. The main target of heart failure therapy is the inhibition of the sympathetic nervous system and renin-angiotensin-aldosterone system. The angiotensin receptor blockers represent a breakthrough in the treatment of heart failure with a demonstrated effect on reduction of cardiovascular events. However, new perspectives derive from latest drugs developed for diabetes, iron deficiency, and hyperkalemia. New frontiers are also opened to the development of neurohormonal therapies, antagonists of inflammatory mediators, inotropic agents, and cell-based treatments.
近几十年来，心力衰竭的治疗取得了相当大的进展。心力衰竭治疗的主要目标是抑制交感神经系统和肾素-血管紧张素-醛固酮系统。血管紧张素受体阻滞剂在心力衰竭治疗方面取得了突破，已被证明可降低心血管事件的发生。然而，最新用于治疗糖尿病、缺铁和高钾血症的药物为心力衰竭的治疗提供了新的视角。神经激素治疗、炎症介质拮抗剂、正性肌力药物和基于细胞的治疗也开辟了新的领域。
